... to in the content or advertisements. 2025 Liquid biopsy Targeted therapy Personalized medicine Metastatic breast cancer In recent decades, we have witnessed a paradigm shift in the treatment of breast cancer. Initially, breast cancer was treated radically with debilitating surgery as all cancer...

... into clinical practice. However, MRD monitoring by ctDNA quantification alone does not allow the reliable detection of 100% of unilocular recurrences and should be complemented by the use of conventional imaging techniques. In general, liquid biopsies for monitoring minimal residual disease are becoming more...

... to in the content or advertisements. 2024 Liquid biopsy Cell-free DNA Circulating tumor DNA Gastrointestinal cancers In 2018, an estimated 4.8 million new cases of gastrointestinal (GI) cancers were reported, with approximately 3.4 million associated deaths. These malignancies alone cause...

...Shirley Cheng; Edward Tri Nguyen; Ian Pagano; Jami Aya Fukui Introduction: Breast cancer is the most prevalent cancer and the second leading cause of cancer death among women in the United States. Liquid biopsy is becoming a more commonly accepted method in clinical practice. Thus, there is a need...

... limited. Most importantly, liquid biopsy-guided treatment interventions have been investigated in several trials. In patients with hormone receptor-positive and HER2-negative MBC, CTC-driven therapy choices resulted in similar PFS to physician’s choice treatment. Recently, the DETECT III trial has shown...

... to in the content or advertisements. 2018 Cabazitaxel CGA Liquid biopsy Neuroendocrine NSE Delivering precision medicine requires the incorporation of tumor heterogeneity in treatment decision-making [ 1 ]. Clinical experience in patients with metastatic castration-resistant prostate cancer...

... tumor cells or tumor cell products in blood samples (liquid biopsy), which in principle might reflect all subclones present at that specific time point and allow sequential monitoring of disease evolution. Liquid biopsies inform on circulating tumor cells as well as tumor-derived cell-free nucleic acids...

...Nikolas von Bubnoff Summary Malignant tumors release tumor cells and fragments of nucleic acids into the bloodstream. Liquid biopsies are non-invasive blood tests that detect circulating tumor cells (CTC) and circulating nucleic acids such as mRNA, microRNA, and cell-free circulating tumor DNA...

.... 2017 Esophageal cancer Metastasis Circulating tumor cells Liquid biopsy Esophageal cancer (EC) is an increasing entity with an incidence of 7,200 newly diagnosed patients prognosticated in 2016 in Germany [ 1 ]. The effective 5-year overall survival (OS) is 20% [ 1 ]. Most of the cases...

... in performing biopsies of metastatic lesions, the phenotype of the primary tumor most often determines the treatment decisions in metastatic breast cancer. Liquid biopsy allows the analysis of several circulating biomarkers like circulating tumor cells (CTCs) or circulating tumor DNA (ctDNA) in peripheral blood...